Gout - Complete Guide to Gout!
Answers to your Gout Questions
(Reuters) – BioCryst Pharmaceuticals Inc said its experimental hepatitis C drug showed promise in preclinical studies, sending its shares up as much as 16 percent to their highest in more than seven months. Additional non-clinical experiments on the drug are ongoing or planned, the company said in a statement on Wednesday. BioCryst, which is also testing potential cancer, influenza and gout …
Excerpt from:
BioCryst hep C drug shows promise, shares jump
A new gout treatment being developed by BioCryst (NASDAQ:BCRX) has achieved positive phase 2 clinical trial results supporting the advance of the drug candidate into late stage clinical studies and boosting the company’s case for finding a drug partner to take on the compound. BioCryst, a Durham, North Carolina-based biopharmaceutical company, is studying the compound called
Continued here:
Gout treatment from BCRX shines in trials; company eyes phase 3 or partner
According to a phase II clinical trial, the drug rilonacept, which inhibits the protein interleukin-1 (IL-1), substantially reduces acute gout flares that occur at the start of uric acid-reducing therapy and is noted to be generally well tolerated with no serious infections or serious adverse events occurring in relation to the treatment. The findings of the first placebo controlled study, in …
View the original here:
Gout Flares – Rilonacept Effective, According To Clinical Trial
URL Pharma granted exclusive rights to distribute Colchicine, an ancient remedy for inflammation, after spending tens of millions on getting the drug FDA approved
BioCryst Pharmaceuticals Inc.
Read More:
BioCryst says gout drug worked in mid-stage trial
Savient Pharmaceuticals Inc. releases a new drug offering relief to patients who have few options when it comes to managing the pain that comes with gout.
Read the original post:
New Drug Offers Pain Relief To Gout Patients
A new drug for gout could help very sick gout patients who don’t get better with usual treatment, according to a new study.
Read the original:
New gout drug may help severely affected: Study
Rounding up Wednesday’s news in the drug space.
View article:
Novartis Touts Gout Success, Watson Makes A Generic Buy
Novartis said Wednesday late-stage trials showed its gout treatment Ilaris, which has already been filed for approval in the U.S. and elsewhere, was effective in reducing patients’ pain and limiting the risk of new attacks, potentially paving the way for the drug to become a blockbuster.
See the original post:
New Gout Drug Successful in Late-Stage Trials
